Media.Player

suramab, a new pharmaceutical compound with antiangiogenic effects

总结

Suramab is the brand name of a new combination of drugs made up of suramin and bevacizumab. Suramab has antiangiogenic properties that can be applied to oncological and ophthalmological diseases.



The european patent (EP 2186529 B1) was granted in March 2012.

The US patent is still pending



This can be seen in the patent file

合作类型

License agreement

附加资料

Patent Number: CN100446394C
Application Number: CN2002800104A
Inventor: Zhubang Liao | Minxi Pang | Yijie Pan
Priority Date: 17 Jan 2001
Priority Number: CN100446394C
Application Date: 11 Jan 2002
Publication Date: 24 Dec 2008
IPC Current: H02M0003335 | H02M000100 | H02M000142 | H02M0007155
Assignee Applicant: The University of Hong Kong
Title: High-efficiency AC-DC converter with power factor corrector | Alternating direct current converter with power factor corrector
Usefulness: High-efficiency AC-DC converter with power factor corrector | Alternating direct current converter with power factor corrector
Summary: To enable control of switching and allow operation in soft switching mode.
Novelty: Power converter with power factor correction and which incorporates zero voltage switching

主要类别

生物医学

细分类别

医疗化妆品

申请号码

MX2008000104

分类

Issued patent

覆盖范围

Great Britain, Ireland, Sweden, Denmark, The Netherland, Germany, Spain, France

专利信息

to be negotiated

国家/地区

阿根廷